Loading the player ...


This activity focuses on:

  • The latest data with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)

  • Personalized migraine treatment

  • Factors that influence treatment

  • Strategies to improve therapeutic adherence

  • Shared decision-making

Jessica Ailani, MD, FAHS, FAAN, and Richard Wenzel, PharmD, also highlight a patient whiteboard they and ACHL developed to help educate patients on CGRP mAbs and how to ensure their voices are heard in their migraine care. Open the door to the possibilities and share this whiteboard with all of your patients with migraine.


  • Jessica Ailani, MD, FAHS, FAAN

    Director, MedStar Georgetown Headache Center Washington, DC

  • Richard Wenzel, PharmD

    Consultant Pharmacist

    Chicago Headache Center & Research Institute Chicago, IL


  • Migraine is a disabling neurological disease with symptoms that include:

  • Moderate or severe unilateral or bilateral headache

  • Nausea/vomiting

  • Sensitivity to light, noise, and/or smells

  • Migraine symptoms may last from four hours to several days

  • 15.9% of all adults suffer from migraine and severe headache

  • Migraine accounts for over 4.3 million office visits yearly

  • Roughly 40% of US adults with migraine are unemployed

  • CGRP, or calcitonin gene-related peptide is a neuropeptide that has been shown to increase during migraine

  • During a migraine attack, CGRP causes the brain blood vessels to swell and send pain signals to the brain

  • CGRP inhibitors, or CGRP monoclonal antibodies (mAbs) help prevent migraine by targeting the CGRP signaling pathway by blocking either the CGRP protein or the CGRP receptor

Supported by an educational grant from Lundbeck.